A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. - Wikidata - awgldk - TriplyDB

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.

http://www.wikidata.org/entity/Q33425581

about

Telomere and Telomerase Therapeutics in Cancer Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations.Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis.Polycythemia Vera Management and Challenges in the Community Health Setting.Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy Fibroblast dynamics as an in vitro screening platform for anti-fibrotic drugs in primary myelofibrosis.New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.Role of Telomeres and Telomerase in Aging and Cancer.Ruxolitinib therapy and telomere length in myelofibrosis.Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma Social Media and Myeloproliferative Neoplasms (MPN)--Focus on Twitter and the Development of a Disease-specific Community: #MPNSM.What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?Myeloproliferative neoplasms: A decade of discoveries and treatment advances.Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone.The evolution and clinical relevance of prognostic classification systems in myelofibrosis.Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.Targeting telomerase with radiolabeled inhibitors.Understanding TERT Promoter Mutations: A Common Path to Immortality.Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?Blast-phase myeloproliferative neoplasms: risk factors and treatment approaches.Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms.Friend or foe? Telomerase as a pharmacological target in cancer and cardiovascular disease.New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment.Primary myelofibrosis and its targeted therapy.Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.Myelofibrosis: an update on drug therapy in 2016.Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.The role of the extracellular matrix in primary myelofibrosis.Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.Telomere-driven diseases and telomere-targeting therapies.Management of myelofibrosis: JAK inhibition and beyond.Splicing factor mutations in MDS RARS and MDS/MPN-RS-T.Developing Cures: Targeting Ontogenesis in Cancer.Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.Telomere Transcripts Target Telomerase in Human Cancer Cells.Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.

P2860

Q26744808-AB2E1418-CF65-4396-BB31-6DFDE9156429 Q26752940-2EFAACB5-8811-4E40-9649-777BE76D309B Q26766319-416FD144-5F34-4464-97FA-F97DB1E371F9 Q27853374-0DE4D053-576F-4C44-BEDB-B095E4011A46 Q30235355-9B5D9A19-90E0-4A30-BD70-2A4E12A0F424 Q33433450-6316774B-D715-4B4B-BD9E-97CC0A818C75 Q33439918-42E6AD06-7595-4089-BEBB-B9E34551007F Q33803036-C41E4C8B-6F79-4A78-A666-D2515852732B Q33914183-5C61C175-F5F9-4F4F-8A5C-0793C8CDF2C5 Q36308248-21C6D31A-2070-4169-97D3-6A253164472B Q36782943-4851E761-BFAA-471F-9D80-F96CCB5645E3 Q36971261-217DF3C2-93BC-4A1F-9D6F-A0D270C801D5 Q37397498-8117E06B-4E76-48E8-B9D1-945F9313D4BD Q37709086-E5989076-03C6-43DE-81BC-0BD8EC3752EF Q38594107-244AA653-318B-462A-BF77-2F13143FA68A Q38597994-6161F161-8AA1-4CB3-8609-56C7E937B9E9 Q38613880-F9393D6C-0BB4-477E-A4E6-1ED867DCFF3A Q38646051-2CD8B54E-B437-4B74-982D-0F7C9B9F2FFA Q38683077-8F2B1693-79FF-4282-B1D1-BD4D3E28EA2F Q38736587-4D9C2718-0A28-44E4-9F4D-6DCC98CE5C45 Q38744397-C6B94789-2C53-4DA4-8128-5BEB88DDE3A0 Q38760235-26481D42-9B23-4D95-B558-99B9362CC677 Q38791273-3674783B-F86B-4D2D-932E-4A060D4AC1E5 Q38844669-DAFD526A-BB75-45C4-821A-FA1419F7CAAC Q38848273-460DAA36-8FBA-4E3A-A3BD-D783AD13849A Q38890930-D18014EC-AAA9-429B-8E51-7E131FF1D0B7 Q38924189-7AFA9EDF-F3D9-4DF8-89BF-DB0F2F2D7FA6 Q38931426-D2796BD7-D1B3-4ED1-BE2D-ABAE3EEFDD63 Q38984578-728F82A8-BDB4-423B-AE1D-633231D1348E Q38989215-97B817A0-10AB-4ABD-A8CA-0A237C0C2EE8 Q39015300-5DBE56A7-1168-4549-8B35-C703844DBBFC Q39117766-ADB940A2-71D8-4A65-ADFC-B8C288AD18BA Q39131365-2BFA272D-BC14-4BEF-84BB-FDFD525495BD Q39158816-D492EA3D-8169-46A0-AF3B-321E0DD6F98F Q39232415-17C444CC-13E6-47D5-B75D-5ACB80E14B0F Q39279998-89FD74F2-359B-48DD-B031-A3D77342D8C9 Q39441380-22DE226D-CADA-41DD-81C8-13521BF640AF Q40094493-7C5F5A03-4481-4ECE-944F-A5BE0622E2D0 Q40571128-28E0A56D-8825-4D16-BA9E-0068FA6D543A Q40603254-23C5237A-1ED5-463C-854F-DD6BAFA0602B

P2860

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.

http://www.wikidata.org/entity/Q33425581

description

2015 nî lūn-bûn

@nan

2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.

@ast

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.

@en

type

label

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.

@ast

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.

@en

prefLabel

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.

@ast

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.

@en

P1433

Q33425581-AD09DBD1-176F-4EF3-8E3C-AE4CF001CAAC

P1476

Q33425581-92AEDFC4-5683-45B8-8446-0B57C6CD1E08

P2093

Q33425581-0E0F8A83-55B2-4379-9A95-59132349B41F

Q33425581-2BF83EA8-A9FD-42D3-B6CF-5E8AFC3854FA

Q33425581-44B7F668-7464-44E9-B161-7E8EBB06EC42

Q33425581-51EC200B-2A6E-42CC-963E-D6B0DBB98AAA

Q33425581-61B96F7F-BA35-426F-B4E4-BCC0F7B876CF

Q33425581-8158A052-3A96-4F7A-B21D-23B47E413BB1

Q33425581-86954AFE-76BE-4E23-83F8-A25E2824BCED

Q33425581-88245232-6EAA-4749-8CA6-DC1DC2EBD353

Q33425581-95217FE3-7870-4BC8-91CE-FA57D24A6247

Q33425581-A3FCD763-C801-4F77-9AC1-6811BF1B8BC7

P304

Q33425581-F8FC2879-FC50-44BB-8B36-8007E8E40863

P31

Q33425581-FBA717C6-6E1B-4919-8484-2F5AF94AAF75

P356

Q33425581-AAD2F3A2-4A9F-49AB-8D3E-4D9914BFF719

P407

Q33425581-DAE3E6A6-46DF-46C2-9CDB-BEFD7FE08944

P433

Q33425581-5A4A7EFF-3C10-4169-9CF4-FF5CEB77EEBE

P478

Q33425581-AF8A9480-741D-4EB4-BBBE-C6D28DA33FEA

P50

Q33425581-7CBDBA85-3B7E-4962-B66A-030087BBB5CB

P577

Q33425581-A358AD19-B024-411E-8C4E-7C5037755E77

P698

Q33425581-8466BE43-1C32-4F86-8769-36DF4D37E36B

P356

P1433

The New England Journal of Medicine

P1476

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.

@en

P2093

Animesh Pardanani

http://www.w3.org/2001/XMLSchema#string

Christy M Finke

http://www.w3.org/2001/XMLSchema#string

Curtis A Hanson

http://www.w3.org/2001/XMLSchema#string

Darci L Zblewski

http://www.w3.org/2001/XMLSchema#string

Emnet Wassie

http://www.w3.org/2001/XMLSchema#string

Kebede H Begna

http://www.w3.org/2001/XMLSchema#string

Lauren Schimek

http://www.w3.org/2001/XMLSchema#string

Mrinal M Patnaik

http://www.w3.org/2001/XMLSchema#string

Naseema Gangat

http://www.w3.org/2001/XMLSchema#string

Rebecca R Laborde

http://www.w3.org/2001/XMLSchema#string

P304

908-919

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1310523

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

373

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26332545

http://www.w3.org/2001/XMLSchema#string